Aphios®
Presents Nanoencapsulated Anthrax Vaccine Adjuvant Technology
At BARDA Industry Day
Woburn,
MA — October 21, 2011 —
Aphios® Corporation announced today that Dr.
Judith Palmer-Castor, Directory of Clinical and Regulatory
Affairs, and Dr. Jay Jayarama, Director of Virology, will
present Aphios’ nanoencapsulated anthrax vaccine adjuvant
technology at BARDA Industry Day: Contracting for Countermeasures
at the Sheraton Boston Hotel on October 17th–19th.
This event is hosted by the Biomedical Advanced Research
and Development Authority (BARDA) and the Office of Acquisitions
Management, Contacts and Grants (AMCG).
Biodegradable polymer nanospheres can be utilized for the
controlled release of potent vaccine antigens. There are
significant barriers to commercialization with conventional
polymer nanospheres technologies. Aphios’ use of SuperFluids™
reduces exposure of vaccine antigens to potentially denaturing
organic solvents such as methylene chloride and ethyl acetate,
and improves the stability of vaccine antigens in the body
at ambient temperature for long periods, thereby enhancing
the capability of nanoencapsulated vaccine antigens to induce
the production of protective and neutralizing antibodies.
Other benefits include adjuvant stimulation of the immune
system by the nanospheres, and improved shelf stability
of the vaccine preparation.
This controlled release vaccine delivery technology, SFS-PNS,
has the capability to deliver different types and combinations
of HIV or Influenza vaccine candidates including whole inactivated
virus particles, DNA plasmids and/or subunit protein antigens
such as recombinant protein antigen (rPA) used in anthrax
vaccines.
Aphios® Corporation is a green biotechnology company
developing enabling technology platforms for improved drug
discovery and manufacturing, nanotechnology drug delivery
and pathogenic drug safety. Based on these platforms, Aphios
is developing enhanced therapeutic products for health maintenance,
disease prevention and the treatment of certain cancers,
infectious diseases and central nervous system disorders,
such as Alzheimer ’s disease.
The Biomedical Advanced Research and Development Authority
(BARDA), a component of the U.S. Department of Health and
Human Services, supports the advanced research, development,
acquisition, and stockpiling of medical countermeasures
(drugs, biological therapeutics, vaccines, diagnostics,
and non-pharmaceutical countermeasures) against Chemical,
Biological, Radiological, and Nuclear (CBRN) WMD threats,
pandemic influenza, and emerging infectious diseases.
###
